Racial and ethnic disparities in human papillomavirus (HPV) vaccine uptake among United States adults, aged 27-45 years

ABSTRACTIn 2018, the Food and Drug Administration expanded the age of eligibility for the human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are racial/ethnic disparities in HPV vaccine uptake for this age-group following this expanded recommendation. We aimed to i...

Full description

Saved in:
Bibliographic Details
Main Authors: Natalie L. Rincon (Author), Kelsey Rae McDowell (Author), Darien Weatherspoon (Author), Tiarney D. Ritchwood (Author), Daniel J. Rocke (Author), Eric Adjei Boakye (Author), Nosayaba Osazuwa-Peters (Author)
Format: Book
Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0280bc3e55d34b668ffcd0835c45f41d
042 |a dc 
100 1 0 |a Natalie L. Rincon  |e author 
700 1 0 |a Kelsey Rae McDowell  |e author 
700 1 0 |a Darien Weatherspoon  |e author 
700 1 0 |a Tiarney D. Ritchwood  |e author 
700 1 0 |a Daniel J. Rocke  |e author 
700 1 0 |a Eric Adjei Boakye  |e author 
700 1 0 |a Nosayaba Osazuwa-Peters  |e author 
245 0 0 |a Racial and ethnic disparities in human papillomavirus (HPV) vaccine uptake among United States adults, aged 27-45 years 
260 |b Taylor & Francis Group,   |c 2024-12-01T00:00:00Z. 
500 |a 10.1080/21645515.2024.2313249 
500 |a 2164-554X 
500 |a 2164-5515 
520 |a ABSTRACTIn 2018, the Food and Drug Administration expanded the age of eligibility for the human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are racial/ethnic disparities in HPV vaccine uptake for this age-group following this expanded recommendation. We aimed to identify any disparities in HPV vaccine in 27 to 45 year-olds based on sociodemographic factors. We analyzed nationally representative, cross-sectional data from the 2019 National Health Interview Survey (n = 9440). Logistic regression models estimated the odds of vaccine uptake (receipt of ≥1 vaccine dose) based on sociodemographic factors. Participants were mostly Non-Hispanic Whites (60.7%) and females (50.9%). In adjusted models, females had over three times greater odds of vaccine uptake compared to males (aOR = 3.58; 95% CI 3.03, 4.23). Also, compared to Non-Hispanic Whites, Non-Hispanic Blacks were 36% more likely (aOR = 1.36; 95% CI 1.09, 1.70), and Hispanics were 27% less likely (aOR = 0.73; 95% CI 0.58, 0.92) to receive the vaccine. Additionally, individuals without a usual place of care had lower odds of vaccine uptake (aOR = 0.72; 95% CI 0.57, 0.93), as were those with lower educational levels (aORhigh school = 0.62; 95% CI 0.50, 0.78; aORsome college = 0.83; 95% CI 0.70, 0.98). There are disparities in HPV vaccine uptake among 27 to 45 year-olds, and adult Hispanics have lower odds of receiving the vaccine. Given the vaccine's importance in cancer prevention, it is critical that these disparities are addressed and mitigated. 
546 |a EN 
690 |a Human papillomavirus (HPV) 
690 |a HPV vaccine uptake 
690 |a racial disparities 
690 |a adults aged 27-45 years 
690 |a National Health Interview Survey (NHIS) 
690 |a expanded HPV vaccine eligibility 
690 |a Immunologic diseases. Allergy 
690 |a RC581-607 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) 
787 0 |n https://www.tandfonline.com/doi/10.1080/21645515.2024.2313249 
787 0 |n https://doaj.org/toc/2164-5515 
787 0 |n https://doaj.org/toc/2164-554X 
856 4 1 |u https://doaj.org/article/0280bc3e55d34b668ffcd0835c45f41d  |z Connect to this object online.